BRIEF published on 12/11/2024 at 07:34, 1 year 6 months ago Evotec SE and Novo Nordisk Launch LAB eN² Projects for Drug Discovery Drug Discovery Evotec SE Novo Nordisk Cardiometabolic Diseases LAB EN²
PRESS RELEASE published on 12/11/2024 at 07:29, 1 year 6 months ago Evotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk Evotec SE announces selection of first projects for LAB eN² drug discovery accelerator with Novo Nordisk, focusing on cardiometabolic diseases from academic institutions Drug Discovery Evotec SE Novo Nordisk Cardiometabolic Diseases LAB EN²
BRIEF published on 11/29/2024 at 07:36, 1 year 6 months ago Evotec Announces COO Departure and Internal Restructuring Pharmaceuticals Management Change Evotec COO Departure Internal Restructuring
PRESS RELEASE published on 11/29/2024 at 07:31, 1 year 6 months ago Evotec announces change in Management Board Evotec SE announces the departure of Chief Operating Officer Dr Craig Johnstone effective December 31, 2024, with internal distribution of responsibilities. Management praises Johnstone's contribution and commitment Global Operations Chief Operating Officer Evotec SE Management Board Dr Craig Johnstone
BRIEF published on 11/22/2024 at 17:00, 1 year 6 months ago Evotec SE Comments on Withdrawal of Halozyme's Offer Shareholder Value Evotec SE Acquisition Proposal Halozyme Therapeutics Non-binding Offer
PRESS RELEASE published on 11/22/2024 at 16:55, 1 year 6 months ago EQS-Adhoc: Comment on withdrawn non-binding offer Evotec SE acknowledges withdrawal of non-binding offer by Halozyme Therapeutics Inc. for acquisition. Management reiterates confidence in standalone strategy Acquisition Evotec SE Halozyme Therapeutics Inc. Withdrawn Offer Standalone Strategy
BRIEF published on 11/14/2024 at 22:56, 1 year 7 months ago Evotec SE Responds to Interest from Halozyme Evotec SE Takeover Halozyme Therapeutics Expression Of Interest EUR 11 Per Share
PRESS RELEASE published on 11/14/2024 at 22:51, 1 year 7 months ago EQS-Adhoc: Comment on media report Evotec SE receives non-binding expression of interest from Halozyme Therapeutics Inc. for a takeover offer of EUR 11.00 per share Evotec SE Takeover Offer Expression Of Interest Halozyme Therapeutics Inc. EUR 11.00 Per Share
BRIEF published on 11/06/2024 at 07:05, 1 year 7 months ago Evotec SE Reports Strategic Progress and Revenue Growth Amid Challenges Strategic Partnerships 2024 Forecasts Biologics Growth Evotec Financial Results Priority Reset Initiative
PRESS RELEASE published on 11/06/2024 at 07:00, 1 year 7 months ago Evotec SE reports 9M 2024 results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions Evotec SE reports 9M 2024 results with strategic progress amid challenging market conditions. New partnerships and operational milestones achieved Financial Results Evotec SE Partnerships 9M 2024 Operational Milestones
Published on 06/18/2026 at 18:00, 1 hour 7 minutes ago BEACN Closes Second Series Under Loan Program and Previews BEACN App Version 1.4
Published on 06/18/2026 at 17:30, 1 hour 37 minutes ago Sekur Private Data Appoints Nathan R. Price as Special Advisor for Diplomacy & Intelligence
Published on 06/18/2026 at 15:50, 3 hours 17 minutes ago Pentagon I Capital Corp. and Prospectiva Resources Ltd. Announce Financing
Published on 06/18/2026 at 15:00, 4 hours 7 minutes ago Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
Published on 06/18/2026 at 14:30, 4 hours 37 minutes ago Voting Results from Solitario Resources Corp Annual Meeting Held June 17, 2026
Published on 06/18/2026 at 18:30, 36 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/18/2026 at 18:25, 41 minutes ago Sopra Steria achives Level 2 Responsible Digital Label and strengthens its responsible digital strategy
Published on 06/18/2026 at 17:45, 1 hour 22 minutes ago 2CRSi SA: 2CRSi disputes the content of the document published by Grizzly Research and is preparing a substantiated response calling for the suspension of trading in its shares
Published on 06/18/2026 at 18:00, 1 hour 7 minutes ago Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 1 hour 22 minutes ago EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 1 hour 28 minutes ago Statement of transactions in own shares from June 8, 2026 to June 12, 2026
Published on 06/18/2026 at 09:06, 10 hours 1 minute ago Eiffage, member of the NSORe joint venture, wins the contract for a converter station for the NSC2 offshore grid connection project in Germany
